Updates are available Correction dated 2023-06-09
Click to view Correction: https://doi.org/10.1038/s44161-023-00301-2
-
Authors
Warthi, Ganesh
Faulkner, Jessica L.
Doja, Jaser
Ghanam, Amr R. http://orcid.org/0000-0001-8269-1420
Gao, Pan
Yang, Allison C.
Slivano, Orazio J.
Barris, Candee T. http://orcid.org/0000-0001-5313-6487
Kress, Taylor C.
Zawieja, Scott D.
Griffin, Susan H.
Xie, Xiaoling
Ashworth, Alan
Christie, Christine K.
Bryant, William B. http://orcid.org/0000-0002-3332-4330
Kumar, Ajay
Davis, Michael J.
Long, Xiaochun
Gan, Lin
Belin de Chantemèle, Eric J.
Lyu, Qing R. http://orcid.org/0000-0002-1325-6828
Miano, Joseph M. http://orcid.org/0000-0001-7522-3207
-
Funding
Funding for this research was provided by:
American Heart Association (CDA858380, 17POST3360938)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL146948, HL143198, HL122578, HL122686, HL139794, HL155265, HL138987, HL147476)
U.S. Department of Health & Human Services | NIH | National Eye Institute (EY026614)
- License Information
-
More Information
Article History
Received: 19 February 2022
Accepted: 29 September 2022
First Online: 11 November 2022
Change Date: 9 June 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s44161-023-00301-2
Competing interests
: A.A. is a co-founder of Tango Therapeutics, Azkarra Therapeutics, Ovibio Corporation and Kytarro; a member of the board of Cytomx and Cambridge Science Corporation; a member of the scientific advisory board of Genentech, GLAdiator, Circle, Bluestar, Earli, Ambagon, Phoenix Molecular Designs and Trial Library; a consultant for SPARC, ProLynx and GlaxoSmithKline; receives grant or research support from SPARC and AstraZeneca; and holds patents on the use of PARP inhibitors held jointly with AstraZeneca from which he has benefited financially (and may do so in the future). The patents are unrelated to any aspect of the current study. All other authors declare no competing interests.
